AKBA vs. SNOA
AKBA (Akebia Therapeutics, Inc.) and SNOA (Sonoma Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — AKBA in Biotechnology, SNOA in Drug Manufacturers - Specialty & Generic. Over the past 10 years, AKBA returned -16.86%/yr vs -47.32%/yr for SNOA. At a 0.12 correlation, their price movements are largely independent.
Performance
AKBA vs. SNOA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AKBA achieves a -13.04% return, which is significantly higher than SNOA's -65.38% return. Over the past 10 years, AKBA has outperformed SNOA with an annualized return of -16.86%, while SNOA has yielded a comparatively lower -47.32% annualized return.
AKBA
- 1D
- -2.10%
- 1M
- 51.43%
- 6M
- -7.89%
- YTD
- -13.04%
- 1Y
- -64.38%
- 3Y*
- 6.78%
- 5Y*
- -16.31%
- 10Y*
- -16.86%
SNOA
- 1D
- 0.00%
- 1M
- 15.60%
- 6M
- -65.48%
- YTD
- -65.38%
- 1Y
- -65.10%
- 3Y*
- -61.22%
- 5Y*
- -61.31%
- 10Y*
- -47.32%
AKBA vs. SNOA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AKBA Akebia Therapeutics, Inc. | -13.04% | -15.26% | 53.23% | 114.90% | -74.47% | -19.29% | -55.70% | 14.29% | -62.81% | 42.84% |
SNOA Sonoma Pharmaceuticals, Inc. | -65.38% | 35.32% | -25.44% | -83.89% | -75.44% | -37.19% | 66.51% | -32.01% | -86.93% | 8.13% |
Correlation
The correlation between AKBA and SNOA is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.16 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.14 |
Correlation (All Time) Calculated using the full available price history since Mar 20, 2014 | 0.12 |
The correlation between AKBA and SNOA shifts across timeframes, from 0.12 (all time) to 0.27 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
AKBA:
$375.56M
SNOA:
$2.12M
AKBA:
-$0.08
SNOA:
-$2.01
AKBA:
1.62
SNOA:
0.12
AKBA:
$232.40M
SNOA:
$17.72M
AKBA:
$188.28M
SNOA:
$6.76M
AKBA:
$2.84M
SNOA:
-$3.31M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AKBA vs. SNOA — Risk / Return Rank
AKBA
SNOA
AKBA vs. SNOA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Akebia Therapeutics, Inc. (AKBA) and Sonoma Pharmaceuticals, Inc. (SNOA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AKBA | SNOA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.19 | ||
| Sortino ratioReturn per unit of downside risk | -0.01 | ||
| Omega ratioGain probability vs. loss probability | 0.83 | 0.85 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | -0.83 | -0.84 | +0.01 |
| Martin ratioReturn relative to average drawdown | -1.16 | -1.41 | +0.25 |
Loading charts...
Drawdowns
AKBA vs. SNOA - Drawdown Comparison
The maximum AKBA drawdown since its inception was -99.14%, roughly equal to the maximum SNOA drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for AKBA and SNOA.
Loading charts...
Drawdown Indicators
| AKBA | SNOA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.14% | -100.00% | +0.86% |
Max Drawdown (1Y)Largest decline over 1 year | -78.23% | -81.12% | +2.89% |
Max Drawdown (3Y)Largest decline over 3 years | -78.23% | -95.66% | +17.43% |
Max Drawdown (5Y)Largest decline over 5 years | -92.94% | -99.38% | +6.44% |
Max Drawdown (10Y)Largest decline over 10 years | -98.73% | -99.93% | +1.20% |
Current DrawdownCurrent decline from peak | -95.20% | -100.00% | +4.80% |
Average DrawdownAverage peak-to-trough decline | -77.43% | -91.18% | +13.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 55.92% | 48.42% | +7.50% |
Volatility
AKBA vs. SNOA - Volatility Comparison
Akebia Therapeutics, Inc. (AKBA) has a higher volatility of 16.15% compared to Sonoma Pharmaceuticals, Inc. (SNOA) at 11.97%. This indicates that AKBA's price experiences larger fluctuations and is considered to be riskier than SNOA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AKBA | SNOA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.15% | 11.97% | +4.18% |
Volatility (6M)Calculated over the trailing 6-month period | 52.54% | 66.51% | -13.97% |
Volatility (1Y)Calculated over the trailing 1-year period | 75.55% | 104.60% | -29.05% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.74% | 119.34% | -27.60% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 84.76% | 103.95% | -19.19% |
Dividends
AKBA vs. SNOA - Dividend Comparison
Neither AKBA nor SNOA has paid dividends to shareholders.
Financials
AKBA vs. SNOA - Financials Comparison
This section allows you to compare key financial metrics between Akebia Therapeutics, Inc. and Sonoma Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AKBA vs. SNOA - Profitability Comparison
AKBA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Akebia Therapeutics, Inc. reported a gross profit of 41.25M and revenue of 53.54M. Therefore, the gross margin over that period was 77.1%.
SNOA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Sonoma Pharmaceuticals, Inc. reported a gross profit of 1.65M and revenue of 4.35M. Therefore, the gross margin over that period was 37.9%.
AKBA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Akebia Therapeutics, Inc. reported an operating income of -4.70M and revenue of 53.54M, resulting in an operating margin of -8.8%.
SNOA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Sonoma Pharmaceuticals, Inc. reported an operating income of -678.00K and revenue of 4.35M, resulting in an operating margin of -15.6%.
AKBA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Akebia Therapeutics, Inc. reported a net income of -9.05M and revenue of 53.54M, resulting in a net margin of -16.9%.
SNOA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Sonoma Pharmaceuticals, Inc. reported a net income of -819.00K and revenue of 4.35M, resulting in a net margin of -18.8%.
Frequently Asked Questions
AKBA and SNOA have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AKBA has higher volatility (16.15%) compared to SNOA (11.97%). In terms of maximum drawdown, AKBA dropped -99.14% vs SNOA's -100.00%.
SNOA currently has the higher Sharpe Ratio (-0.67 vs -0.86), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AKBA and SNOA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer